Highnoon Laboratories : Transmission of Annual Report for the year ended 31 December 2022
April 07, 2023 at 06:35 am
Share
Innovate to
Accelerate
A n n u a l R e p o r t 2 0 2 2
Annual Report 2022
1
CONTENTS
Our Core Values
26
Financial Highlights
28
Company Information
29
Notice of Annual General Meeting
30
Chairman's Review
36
Directors' Report to the Share holders
40
Six Years at a Glance
52
Graphical Presentation
54
Statement of value addition and its distribution
55
Horizontal & Vertical Analysis
56
Pattern of Shareholding
60
Statement of Compliance with Listed Companies
64
(Code of Corporate Governance) Regulations, 2019
Independent Auditor's Review Report to the
66
members of Highnoon Laboratories Limited
Financial Statements of Highnoon Laboratories Limited
Independent Auditor's Report
68
Unconsolidated Statement of Financial Position
72
Unconsolidated Statement of Profit or Loss
74
Unconsolidated Statement of Comprehensive Income
75
Unconsolidated Statement of Cash Flows
76
Unconsolidated Statement of Changes in Equity
79
Unconsolidated Notes to the Financial Statements
80
Consolidated Financial Statements
Group Directors' Report to the Shareholders
146
Independent Auditor's Report
150
Consolidated Statement of Financial Position
154
Consolidated Statement of Profit or Loss
156
Consolidated Statement of Comprehensive Income
157
Consolidated Statement of Cash Flows
158
Consolidated Statement of Changes in Equity
161
Consolidated Notes to the Financial Statements
162
Proxy Form
Ballot Paper
2
Highnoon Laboratories Limited
Innovate to Accelerate
We believe in taking risks and embracing change. We're constantly leveraging modern technologies, creating differentiated offerings, pushing the boundaries of
what's possible and seeking new ways to accelerate our progress.
Innovation breeds progress and growth. And we're determined to create a culture of creativity and collaboration to encourage our people to think outside the box and embrace new ideas.
At every step, we remind ourselves that these innovations are not only for our profitability. We also have to make a positive impact on the world. Whether it's supporting local communities, reducing our environmental footprint, or promoting ethical business practices, we are making a meaningful difference through our Environmental Social Governance program.
So let us embrace innovation and all that it represents. Let us be bold, daring, curious and creative and use our passion to strive for a brighter future. For with innovation, anything is possible, and possibilities are limitless.
Achieve
to Celebrate
A n n u a l R e p o r t 2 0 2 2
Empower to Care
Inform
to Enlighten
Innovate to Sustain
Passion
to Progress
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Highnoon Laboratories Ltd. published this content on 07 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 April 2023 05:34:03 UTC.
Highnoon Laboratories Limited is a Pakistan-based company that is engaged in the manufacturing, importing, selling and marketing of pharmaceutical and allied consumer products. The Company's product categories include cardiology, metabolic, gastroenterology, musculoskeletal, anti-infective, obstetrics and gynecology, pediatrics, allergy, respiratory, and urology. Its cardiology products include Somno, Hitica, Apiban, Pidogrel-AP, Blokium DIU, Epliron, Sacuvia, Ivaset, Rivaro, Valforge and Herbesser. Its metabolic products include Xormet XR, MetFormin HCI, Diajard-MXR, Diajard-M and Diajard. The Company's gastroenterology products include Liv 52, Rabecid and Racedo. Its musculoskeletal products include Flexa Plus, Airtal ER and Tamadol. The Company's pediatric products include Bonisan, Cogniza, Flu Ace, Prospan and Tres Orix Forte. Its allergy products include Leviva and Kestine. Its Respiratory products include Combivair Forte, Sprahaler Respules, Foracort HFA Inhaler and Rotaflo.